51st Annual Meeting & ToxExpo - Society of Toxicology

Society of Toxicology 2012
Scientific
Workshops
The Thematic Track information can be found on pages 8–9.
• Enzymatic Functions Defined by Tracking Redox Reactions: The
Example of Manganese Superoxide Dismutase. Marcelo Bonini,
University of Illinois at Chicago, Chicago, IL.
• Intra- and Intercellular Signaling Pathways As Modulators of
Free Radical Toxicity. Lars-Oliver Klotz, University of Alberta,
Edmonton, Alberta, Canada.
• Free Radicals and Oxidized Macromolecules: Roles in Biomarker
Toxicology. Maria Kadiiska, NIEHS/NIH, Research Triangle Park,
NC.
• Distinguishing Free Radical Metabolites of Aromatic Amine
Drugs Based on Reactivity and Their Potential In Vivo Toxicity.
Arno Siraki, University of Alberta, Edmonton, Alberta, Canada.
Clinical Toxicology from Bedside to the
Bench and Back
Chelation Therapy: A Focus on the Risks
and Benefits
Wednesday, March 14, 9:00 AM to 11:45 AM
Chairperson(s): Carl Herbrandson, Minnesota Department of Health,
Saint Paul, MN, and Richard Wang, Centers for Disease Control and
Prevention, Atlanta, GA.
Sponsor:
Occupational and Public Health Specialty Section
Endorsed by:
Clinical and Translational Toxicology Specialty Section
Metals Specialty Section
Chelation is a very important therapy to lessen the occurrence of health
consequences from the exposure to high levels of metals including
selected radionuclides. However, the efficacy of treatment long after
exposure has not been consistently demonstrated. Chelation in cases
where exposures are limited can compromise health. Furthermore,
chelation has been used in attempts to treat diseases for which it has
not been proven effective (e.g., arteriosclerosis and autism). On the
surface, the idea of removing toxic metals from the body is appealing,
but serious health consequences can occur when chelation is improperly
used. Consideration of the perspectives of medical and public
health practitioners on chelation practices are important.
• Chelation Therapy at Different Stages of Life. Deborah Cory-
Slechta, University of Rochester Medical Center, Rochester, NY.
• Chelation Therapy: A Cautionary Tale. Mary Jean Brown, Centers
for Disease Control and Prevention, Atlanta, GA.
• Experimental Evidence of Efficacy and Harm: The Good and
Bad of Chelation Therapy. Donald Smith, University of California,
Santa Cruz, CA.
• Chelation Controversy: What Does This Laboratory Test Mean?
Charles McKay, University of Connecticut School of Medicine,
Hartford, CT.
• Chelation for Heavy Metal Intoxication: A Medical Toxicology
Perspective. Michael Kosnett, University of Colorado School of
Medicine, Denver, CO.
Cooperative Epidemiology and Toxicology
Research: HEI’s National Particle Component
Toxicity (NPACT) Initiative
Wednesday, March 14, 9:00 AM to 11:45 AM
Chairperson(s): Matthew J. Campen, University of New Mexico,
Albuquerque, NM, and Geoffrey Sunshine, Health Effects Institute,
Boston, MA.
Sponsor:
Cardiovascular Toxicology Specialty Section
Endorsed by:
Disease Prevention Task Force
Inhalation and Respiratory Specialty Section
Occupational and Public Health Specialty Section
In 2006, the Health Effects Institute (HEI) funded two major studies
to address the comparative toxicity of components of particulate
matter (PM) at multiple places across the United States where
PM components and the sources of PM would differ. The goal of
the program was to integrate toxicological and epidemiological
approaches to address this issue. Both teams, one led by Sverre Vedal
at the University of Washington, the other by Mort Lippmann at New
York University (NYU), investigated the effects of PM components
on cardiovascular endpoints in the same strain of mouse, ApoE
knockout, but took contrasting approaches. In research conducted
at Lovelace Respiratory Research Institute, Dr. Vedal’s team exposed
the mice to well-characterized, lab-generated pollutant atmospheres
that included vehicular—diesel + gasoline engine emissions—resuspended
road dust, and secondary nitrates and sulfate particles. Dr.
Lippmann’s team exposed the mice to particles concentrated from
ambient air at four sites across the US. The NYU team also collected
PM samples of different size ranges—ultrafine, fine, and coarse—at
these sites to evaluate cardiovascular effects in another strain of mice.
The epidemiological analyses in both studies used well-established
cohorts with participants throughout the US and with some overlap
between the locations studied by both groups. Dr. Vedal’s team
focused on evaluating associations between long-term exposure to
PM components with cardiovascular endpoints in participants in the
Multi-Ethnic Study of Atherosclerosis (MESA) and Women’s Health
Initiative (WHI) studies. Dr. Lippmann’s team evaluated associations
in multiple cities between PM components and daily mortality
and hospital admissions endpoints, as well as between exposures to
components and annual mortality in the American Cancer Society
Thematic Session
94
SOT’s 51 st Annual Meeting